Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer. BELLA is a single-arm, open-label trial with a planned enrollment of 90 women with recurrent, platinum-resistant ovarian cancer at approximately 50 sites in North America, Europe and Asia-Pacific. Patients will receive relacorilant in combination with nab-paclitaxel and bevacizumab. "In our pivotal Phase 3 ROSELLA trial, treatment with relacorilant and nab-paclitaxel improved patients' progression-free and overall survival, without increasing their side effect burden," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "BELLA will examine whether combining relacorilant with two medications – nab-paclitaxel and bevacizum
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics (NASDAQ:CORT) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
- Corcept Therapeutics (NASDAQ:CORT) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Corcept Therapeutics (NASDAQ:CORT) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.MarketBeat
- Assessing Corcept Therapeutics (CORT) Valuation as Relacorilant Nears Key PDUFA Decision and Analyst Optimism Builds [Yahoo! Finance]Yahoo! Finance
CORT
Earnings
- 11/4/25 - Miss
CORT
Sec Filings
- 12/16/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- CORT's page on the SEC website